Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant

Leuk Lymphoma. 2014 Dec;55(12):2967-9. doi: 10.3109/10428194.2014.911862. Epub 2014 Jun 16.

Authors

Aleksandar Radujkovic¹, Michael Hundemer, Christoph Eisenbach, Thomas Luft, Roland Penzel, Hartmut Goldschmidt, Anthony D Ho, Frauke Bellos

Affiliation

¹ Department of Internal Medicine V.

PMID: 24707945
DOI: 10.3109/10428194.2014.911862

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow / pathology
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Leishmaniasis, Visceral / diagnosis*
Leishmaniasis, Visceral / etiology*
Macrophages / parasitology
Macrophages / pathology
Melphalan / administration & dosage
Melphalan / adverse effects*
Multiple Myeloma / complications*
Multiple Myeloma / diagnosis
Multiple Myeloma / therapy
Myeloablative Agonists / administration & dosage
Myeloablative Agonists / adverse effects*
Transplantation, Autologous

Substances

Myeloablative Agonists
Melphalan